LA+PHARMA
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
31-08
abbreviated format · 31 days late
2025
31-12
Financial
Highest result from 2018 to 2025net €127,041 ▲2%
The operating result of €209,612 and the net result of €127,041 are both a record.
31-12
Financial
Equity above €500,000equity €614,605 ▲25.8%
After 7 profitable years in a row, equity reaches €614,605.
28-08
abbreviated format · 28 days late
2024
13-08
abbreviated format · 13 days late
2023
31-08
abbreviated format · 31 days late
2022
31-12
Financial
Equity above €200,000equity €241,506 ▲39.1%
After 4 profitable years in a row, equity reaches €241,506.
30-08
abbreviated format · 30 days late
2021
31-12
Financial
Equity above €150,000equity €173,637 ▲51.6%
After 3 profitable years in a row, equity reaches €173,637.
31-08
abbreviated format · 31 days late
2020
31-12
Financial
Equity above €100,000equity €114,537 ▲360%
After 2 profitable years in a row, equity reaches €114,537.
15-09
abbreviated format · 46 days late
Show earlier events
2019
31-12
Financial
Back to profitnet €16,628
The net result is €16,628, after one loss-making year.
14-08
abbreviated format · 14 days late
2018
10-08
abbreviated format · 10 days late
2017
31-08
abbreviated format · 31 days late
2012
30-05
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank